Status:
COMPLETED
Albumin Infusion Targets on Mortality in Patients With Abdominal Sepsis
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Conditions:
28-day Mortality
Eligibility:
All Genders
18-100 years
Brief Summary
Hypoalbuminemia has been shown to be significantly associated with increased mortality from abdominal sepsis, and early albumin infusion to maintain high serum albumin concentrations may be beneficial...
Detailed Description
Research Background Introduction to Sepsis and Abdominal Sepsis Sepsis is a life-threatening condition characterized by organ dysfunction due to a dysregulated immune response to infection. Abdominal ...
Eligibility Criteria
Inclusion
- Patients admitted to the Intensive Care Department of Southern Hospital of Southern Medical University from September 2017 to June 2022;
- Age ≥ 18 years old;
- Meeting the diagnostic criteria for abdominal infection;
- Patients who meet the diagnostic criteria for sepsis/septic shock;
- Complicated with hypoalbuminemia, i.e. plasma albumin\<30g/L after admission;
- Human serum albumin injection was infused within 24 hours after check-in into the ICU.
Exclusion
- Pregnant or lactating women
- Patients who have not been able to obtain relevant diagnosis and treatment information after ICU check-in
- Patients who repeatedly stay in the ICU
- ICU hospitalization time is less than 24 hours
- Pathological conditions that require albumin treatment in clinical practice (cirrhosis with ascites, post liver transplantation, intestinal malabsorption syndrome, nephrotic syndrome, burns);
Key Trial Info
Start Date :
March 11 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 30 2025
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT06874634
Start Date
March 11 2024
End Date
January 30 2025
Last Update
March 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Critical Care Medicine
Guangzhou, Guangdong, China, 510515